| Acellular Dermal Allograft for the Correction of Eyelid Retraction. |
|
Jun Young Ji, Yoon Duck Kim |
1Department of Ophthalmology, Dankook University College of Medicine, Cheonan, Korea.
2Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea. ydkim@smc.samsung.co.kr |
| 세포성 진피동종이식편을 이용한 안검후퇴교정술 |
|
지준영1,김윤덕2 |
|
Department of Ophthalmology, Dankook University College of Medicine, Cheonan, Korea1 Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea2 |
|
Correspondence:
Jun-Young Ji, M.D.1 |
|
|
| Abstract |
PURPOSE
To evaluate the efficacy and safety of acellular human dermis (AlloDerm) as a spacer graft in the correction of eyelid retraction. METHODS: We used acellular human dermis (AlloDerm) as a spacer in 8 patients with eyelid retraction. Two patients had upper eyelid retraction and 6 had lower eyelid retraction. The causes of the former were congenital (1) and ptosis operation (1), and of the latter were strabismus surgery (1), necrotizing blepharitis (1), blow-out fracture (1), anophthalmic socket contracture (1), cicatricial entropion (1), and lower lid blepharoplasty (1). The follow-up period ranged from 5 to 14 months (mean 9 months). RESULTS: Surgical results in 7 eyelids were satisfactory. There was mild overcorrection in one eyelid with congenital upper eyelid retraction. There were no other complications such as exposure, infection, or rejection. CONCLUSIONS: AlloDerm was easy to manipulate, closely approximated the eyelid tarsus in contour and thickness, and appeared to be nontoxic and nonallergenic. We suggest AlloDerm as the spacer material of choice for the treatment of eyelid retraction. |
| Key Words:
AlloDerm;Eyelid retraction;Spacer |
|
PDF Links
Download Citation
